Prolactinomas are the most common of the hormone-secreting tumors of the pituitary. There are many causes of hyperprolactinemia which must be excluded and an imaging procedure such as MRI or CT is necessary to demonstrate the size and anatomy of the tumor. Dopamine agonist therapy constitutes the primary treatment for prolactinomas, being effective in shrinking tumors as well as normalizing PRL levels. The most effective and best tolerated dopamine agonist is cabergoline, at present. Transsphenoidal surgery is reserved for tumors not responding to dopamine agonists and radiotherapy is rarely done. Because of its established safety profile for the developing fetus, bromocriptine is the preferred dopamine agonist to use to facilitate ovulation and pregnancy. During pregnancy, close to one-quarter of macroprolactinomas can be expected to enlarge significantly while less than 2% of microprolactinomas do so. Tumor enlargement during pregnancy usually responds readily to reinstitution of the dopamine agonist.
- Pituitary Adenoma
- Dopamine Agonist
- Transsphenoidal Surgery
- Pituitary Tumor Transforming Gene
- Tumor Size Reduction
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Unable to display preview. Download preview PDF.
Molitch ME: Prolactin. In S. Melmed, ed.: The Pituitary. Blackwell Scientific Publications, Boston, In Press.
Davies PH: Drug-related hyperprolactinaemia. Adverse Drug React Toxicol Rev 1997;16:83–94.
Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A: Effect of methyl-dopa on prolactin and growth hormone. Brit Med J 1976;1:1186–1188.
Kelley SR, Kamal TJ, Molitch ME: Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia. Am J Physiol 270 (Endocrinol Metab 33):E96–E100, 1996.
Sievertsen GD, Lim VS, Nakawatase C, & Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab 1980;50:846–851.
Hou SH, Grossman S, Molitch ME. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am J Kidney Dis 1985 6:245–249.
Morgan MY, Jakobovits AW, Gore MB et al Serum prolactin in liver disease and its relationship to gynecomastia. 1978 Gut, 19:170–174.
Honbo KS, Herle AJV, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med 1978;64:782–787.
Stryker TD, Molitch ME. Reversible hyperthyrotropinemia, hyperthyroxinemia and hyperprolactinemia due to adrenal insufficiency. Am J Med 1985;79:271–276.
Boyd AE III, Spare S, Bower B, Reichlin S. Neurogenic galactorrhea-amenorrhea. J Clin Endocrinol Metab 1978 47:1374–1377.
Palmer PE, Bogojavlensky S, Bhan AK, Scully RE. Prolactinoma in wall of overian dermoid cyst with hyperprolactinemia. Obstet Gynecol 1990 75:540–543.
Molitch ME, Reichlin S. Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk. Prolactin. Basic and clinical correlates. R.M. MacLeod, M.O. Thomer and U. Scapagnini(eds.) Liviana Press, Padova (1985) pp. 709–719.
Arafah MB, Neki KE, Gold RS, Selman WR: Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab 1995;80:3507–3512.
Bevan JS, Burke CW, Esiri MM, Adams CBT. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med 1987 82:29–32.
Martin TL, Kim M, Malarkey WB. The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab 1985;60:855–858.
Schlechte J, Dolan K, Sherman B, et al: The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989;68:412–418.
Sluijmer AV, Lappöhn RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril1992;58:72–77.
Klijn JGM, Lamberts SWJ, De Jong FH, Docter R, Van Dongen KJ, Birkenhäger JC. The importance of pituitary tumour size in patients with hyperprolactinaemia in relation to hormonal variables and extrasellar extension oftumour. Clin Endocrinol 1980;12:341–355.
Pemicone PJ, Scheithauer B W, Sebo TJ et al: Pituitary carcinoma. Cancer 1997;79:804–812.
Fine SA, Frohman LA. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. J Clin Invest 1978; 61:973–980.
Molitch ME: Pathogenesis of pituitary tumors. Endocrinol Metab Clin N Amer 1987;16: 503–527,1987.
Klibanski A: Further evidence for a somatic mutation theory in the pathogenesis of human pituitary tumors. J Clin Endocrinol Metab 1990;71:1415.
Melmed S: Pathogenesis of pituitary tumors. Endocrinol Metab Clin N Amer 1999;28:1–12.
Clayton RN, Boggild M, Bates AS, Bicknell J, Simpson D, Farell W: Tumour suppressor genes in the pathogenesis of human pituitary tumours. Horm Res 1997;47:185–193.
Barlier A, Pellegrini-Bouiller I, Caccavelli L et al: Abnormal transduction mechanisms in pituitary adenomas. Horm Res 1997;47:227–234.
Pelligrini-Bouiller I, Morange-Ramos A, Barlier A, Gunz G, Enjalbert A, Jaquet P: Pit-1 gene expression in human pituitary adenomas. Horm Res 1997;47:251–258.
Gonsky R, Herman V, Melmed S, Fagin J: Transforming DNA sequences present in human prolactin-secreting pituitary tumors. Mol Endocrinol 1991;5:1687–1695.
Shimon I, Huttner A, Said J, Spirina OM, Melmed S: Heparin-binding secretory transforming gene (hst) facilitates rat lactrotrope cell tumorigenesis and induces prolactin gene transcription. J Clin Invest 1996;97:187–195.
Pei L, Melmed S: Isolation and characterization of a pituitary tumor-specific transforming gene. Mol Endocrinol 1997;11:443–441.
Zhang X, Horwitz GA, Prezant TR et al: Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1999;13:156–166.
Zhang X, Horwitz GA, Heaney AP et al: Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999;84:761–767.
Von Werder K, Eversmann T, Fahlbusch R, Rjosk H-K. Development of hyperprolactinemia in patients with adenomas with and without prior operative treatment. Excerpta Med Int Congr Ser 1982;584:175–188.
March CM, Kletzky OA, Davajan V, et al. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1981;139: 835–844.
Weiss MH, Teal J, Gott P, et al. Natural history of microprolactinomas: six-year follow-up. Neurosurgery 1983;12:180–183.
Koppelman MCS, Jaffe MJ, Rieth KG, Caruso RC, Loriaux DL. Hyperprolactinemia, amenorrhea, and galactorrhea. Ann Intern Med 1984;100:115–121.
Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated.Fertil Seril 1987;48:67–71
Jeffcoate WJ, Pound N, Sturrock NDC, Lambourne J: Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol 1996;45:299–303.
Rigg LA, Lein A, Yen SSC. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 1977;129:454–456.
Scheithauer BW, Sano T, Kovacs KT, Young WF Jr, Ryan N, Randall RV. The pituitary gland in pregnancy. A clinicopathologic and immunohistochemical study of 69 Cases. Mayo Clin Proc 1990;65:461–474.
Molitch ME: Clinical features and epidemiology of prolactinomas in women. In Prolactinomas: Practical Diagnosis and Management, JM Olefsky and RJ Robbins (eds.), Churchill Livingstone, Inc., New York, 67–95, 1986.
Wingrave SJ, Kay CR, Vessey MP: Oral contraceptives and pituitary adenomas. Br Med J 1980;1:685–686.
Molitch ME, Reichlin S. Hyperprolactinemic disorders. Disease-a-Month 1982;28(9):1–58.
Mashchak CA, Kletzky OA, Davajan V, Mishell DR. Clinical and laboratory evaluation of patients with primary amenorrhea. Obstet Gynecol 1981;57:715–721.
Pepperell RJ, Aust F. Prolactin and reproduction. Fertil Steril 1981 35:267–274.
Post KD, Biller BJ, Adelman LS, Molitch ME, Wolpert SM, Reichlin S. Selective transsphenoidal adenomectomy in women with galactorrhea-amenorrhea. JAMA 1979;242:158–162.
Skrabanek P, McDonald D, De Valera E, Lanigan O, Powell D. Plasma prolactin in amenorrhoea, infertility, and other disorders: A retrospective study of 608 patients. Irish J Med Sci 1980;149:236–245.
Kredentser JV, Hoskins CF, Scott JZ. Hyperprolactinemia-a significant factor in female infertility. Am J Obstet Gynecol 1981;139:264–267.
Biller BMK, Baum HBA, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992;75:692–697.
Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992;75:698–703.
Ciccarelli E, Savino L, Carlevatto V, Bertagna A, Isaia GC, Camanni F. Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women. Clin Endocrinol 1988;28:1–6.
Sarkar DK, Yen SSC. Hyperprolactinemia decreases the luteinizing hormone-releasing hormone concentration in pituitary portal plasma: A possible role ß-endorphin as a mediator. Endocrinology 1985 116:2080–2084.
Stevenaert A, Beckers A, Vandalem JL, Hennen G: Early normalization of luteinizing hormone pulsatility after successful transsphenoidal surgery in women with microprolactinomas. J Clin Endocrinol Metab 1986;62:1044–1047.
Glass MR, Shaw RW, Butt WR, Edwards RL, London DR. An abnormality of oestrogen feedback in amenorrhoea-galactorrhoea. British Medical J 1975 3:274–275.
Perryman RL and Thorner MO. The effects of hyperprolactinemia on sexual and reproductive function in men. J Androl 1981;5:233–242.
Heshmati HM, Turpin G, Nahoul K, et al. Testicular response to human chorionic gonadotrophin in chronic hyperprolactinaemia. Acta Endocrinol 1985;108:565–569.
Luboshitzky R, Rosen E, Trestian S, Spitz M. Hyperprolactinaemia and hypogonadism in men: Response to exogenous gonadotrophins. Clin Endocrinol 1979;11:217–223.
Murray FT, Cameron DF Ketchum C. Return of gonadal function in men with prolactinsecreting pituitary tumors. J Clin Endocrinol Metab 1984;59:79–85.
Molitch ME, Elton RL, Blackwell RE et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698–705.
Cameron DF, Murray FT and Drylie DD. Ultrastructural lesions in testes from hyperprolactinemic men. J Androl 1984;5:283–293.
Schwartz MF, Bauman JE and Masters WH. Hyperprolactinemia and sexual disorders in men. Biol Psych 1982;17:861–876.
Leonard MP, Nickel CJ, Morales A. Hyperprolactinemia and impotence: Why, when and how to investigate. J Urol 1989;142:992–994.
Hargreave TB, Richmond JD, Liakatas J, Elton RA, Brown NS. Searching for the infertile man with hyperprolactinemia. Fertil Steril 1981;36(5):630–632.
Biller BMK, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, Sanfilippo J, Webster J, Zacur H: Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999;44(Suppl.):1075–1084.
Biller BMK: Diagnostic evaluation of hyperprolactinemia. J Reprod Med 1999;44(S upp 1.):1095–1099.
Naidich MJ, Russell EJ: Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin N Amer 1999;28:45–79.
Molitch ME: Pituitary incidentalomas. Endocrinol Metab Clin N Amer 26:725–740, 1997.
Sanfilippo JS: Implications of not treating hyperprolactinemia. J Reprod Med 1999;44(Supp 1.):1111–1115.
Molitch ME: Prolactinomas. In S. Melmed, ed.: The Pituitary. Blackwell Scientific Publications, Boston, In Press.
Nelson AT Jr., Tucker HSG Jr., Becker DP. Residual anterior pituitary function following transsphenoidal resection of pituitary macroadenomas. J Neurosurg 1984;61:577–580.
Massoud F, Serri O, Hardy J,Somma M, Beauregard H: Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surg Neurol 1996;45:341–346.
Ciric I, Ragin A, Baumgartner C et al: Complications of transsphenoidal surgery: results of a national survery, review of the literature, and personal experience. Neurosurgery 1997;40:225–237.
Laws ER Jr, Thapar K: Pituitary surgery. Endocrinol Metab Clin N Amer 1999;28:119–131.
Molitch ME: Medical treatment of giant pituitary prolactinomas. In:Controversies in NeurosurgeryAl-Mefty O (ed.), Theime Medical Publishers, Inc., New York, 2–10, 1996.
Schran HR, Bhuta SI, Schwarz HJ, Thorner MO. The pharmacokinetics of bromocriptine in man. In: Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric AspectsGoldstein M, Caine D, Lieberman A, Thorner M. (eds.) Raven Press, NY, 1980, pp. 125–189.
Thorner MO, Schran HF, Evans WS, Rogol AD, Morris JL, MacLeod RM. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J Clin Endocrinol Metab 1980;50:1026–1033.
Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500–509.
Caccavelli L, Feron F, Morange I et al: Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994;60:314–322.
MacLeod RM, Lehmeyer JE. Suppression of pituitary tumor growth and function by ergot alkaloids. Cancer Res 1973;33:849–855.
Thorner MO, Martin WH, Rogol AD, et al. Rapid regression of pituitary prolactinomas during bromocriptine treatment. J Clin Endocrinol Metab 1980;51:438–445.
Warfield A, Finkel DM, Schatz NJ, Savino PJ, Snyder PJ. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. Ann Intern Med 1984;101:783–785.
Dalzell GW, Atkinson AB, Carson DJ, Sheridan B. Normal growth and pubertal development during bromocriptine treatment for a prolactin-secreting pituitary macroadenoma. Clin Endocrinol 1987;169–172.
Landolt AM, Osterwalder V. Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 1984;58:1179–1183.
Esiri MM, Bevan JS, Burke CW, Adams CBT. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab 1986;63:383–388.
Bevan JS, Adams CBT, Burke CW, et al. Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy. Clin Endocrinol 1987;26:541–556.
Johnston DG, Prescott RWG, Kendall-Taylor P, et al. Hyperprolactinemia: long-term effects of bromocriptine. Am J Med 1983;75:868–874.
Ho KY, Smythe GA, Compton PJ, Lazarus L. Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia. Aust NZ J Med 1985;15:213–219.
Liuzzi A, Dallabonzana D, Giuseppe MD, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656–659.
Thorner MO, Perryman RL, Rogol AD, et al. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 1981;53:480–483.
Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Lancet 1984;2:187–192.
Webster J: Dopamine agonist therapy in hyperprolactinemia. J Reprod Med 1999;44(Suppl):1105–1110.
Turner TH, Cookson JC, Wass JAH, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Brit Med J 1984;289:1101–1103.
Vermesh M, Fossum GT, Kletzky OA. Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. Obstet Gynecol 1988;72:693–698.
Jasonni VM, Raffelli R, de March A, Frank G, Flamigni C. Vaginal bromocriptine in hyperprolactinemic patients and puerperal women. Acta Obstet Gynecol Scand 1991;70:493–495.
Katz E, Schran HF, Adashi EY. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy. Obstet Gynecol 1989;73:517–520.
Franks S, Lynch SS, Horrocks PM, Butt WR. Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment. Lancet 1981;2:659–661.
Blackwell RE, Bradley EL, Kline LB, et al. Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study. Fertil Steril 1983;39:744–748.
Kletzky OA, Borenstein R, Mileikowsky GN. Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia. Am J Obstet Gynecol 1986;154:431–435.
Freda PU, Andreadis CI, Khandji AG et al: Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab 2000;85:8–13.
DiSalle E, Ornati G, Giudici D: A comparison of the in vivo and in vitro duration of prolactin lowering effect in rats of FCE 21336, pergolide and bromocriptine. J Endocrinol Invest 1984;7 (Supp11):32.
Strolin BM, Doster P, Barone D, Efthymiopoulos C, Peretti G, Roncucci R: In vivo interaction of CAB with rat brain dopamine receptors labelled with 3H-N-npropylinorapomorphine. Eur J Pharmacol 1990;187:399–408.
Andreotti AC, Pianezzola E, Persiani S, Pacciarini MS, Strolin Benedetti M, Pontiroli AE: Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactinlowering drug after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. J Clin Endocrinol Metab 1995;80:841.
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF for the Cabergoline Comparative Study Group. N Engl J Med 1994;331:904–909.
Motta T, Colombo N, de Vincentiis S, D’Alberton A, Marchini M: Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil Steril 1996;65:440–442.
Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni F, Giordano G: Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol 1989;69:725–728.
Ferrari C, Mattei A, Melis GB, Paracchi A, Muratori M, Faglia G, Sghedoni D, Crosignani PG: Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab 1989;68:1201–1206.
Ferrari C, Paracchi A, mattei Am, de Vincentiis S, D’Alberton A, Crosignani PG: Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992;126:489–494.
Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoefelder JR, Klibanski A: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338–2343.
Delgrange E, Maiter D, Donckier J: Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996;134:454–456.
Motta T, Maggi G, D’Alberton A, Ferrari C, Paracchi A: Twice weekly cabergoline treatment of macroprolactinoma. J Obstet Gynecol 1989;9:334–335.
Page SR, Nussey SS: Cabergoline therapy of a large prolactinoma in a bromocriptineintolerant patient. J Obstet Gynecol 1989;10:156–158.
Melis GB, Mais V, Gambacciani M, Sghedoni D, Paoletti AM, Fioretti P: Reduction in the size of prolactin-producing pituitary tumor after cabergoline administration. Fertil Steril 1989;52:412–415.
Colao A, DeSarno A, Landi ML et al: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574–3579.
Ferrari CI, Abs R, Bevan JS et al: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 1997;46:409–413.
Verhelst J, Abs R, Maiter D et al: Cabergoline in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1999;84:2518–2522.
Colao A, DiSarno A, Sarnacchiaro S, et al: Prolactinomas resistant to standard dopamine-agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab. 1997;82:876–881.
Krupp P, Monka C, Richter K. The safety aspects of infertility treatments. Program of the Second World Congress of Gynecology and Obstetrics, Rio de Janeiro, October, 1988.
Raymond JP, Goldstein E, Konopka P, Leleu MF, Merceron RE, Loria Y. Follow-up of children born of bromocriptine-treated mothers. Hormone Res 1985;22:239–246.
Konopka P, Raymond JP, Merceron RE, Seneze J. Continuous administration of bromocriptine in the prevention of neurologica complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983;146:935–93
Canales ES, GarcÍa IC, Ruiz JE, Zàrate A. Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil Steril 1981;36:524–526.
Ruiz-Velasco V, Tolis G. Pregnancy in hyperprolactinemic women. Fertil Steril 1984;41:793–805.
Robert E, Musatti L, Piscitelli G, Ferrari CI: Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10:333–337.
Pharmacia and Upjohn, Inc. Data on file. July, 1999.
Molitch ME. Management of prolactinomas during pregnancy. J Reprod Med 1999; 44(Suppl):1121–1126.
Narita O, Kimura T, Suganuma N, et al. Relationship between maternal prolactin levels during pregnancy and lactation in women with pituitary adenoma. Acta Obst Gynaecol Jpn 1985;37:758–762.
Divers WA Jr., Yen SSC. Prolactin-producing microadenomas in pregnancy. Obstet Gynecol 1983;61:425–429.
Brodsky JB, Cohen EN, Brown BW Jr, Wu ML, Whitcher C. Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 1980;138:1165–1167.
Editors and Affiliations
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Molitch, M.E. (2001). Prolactinomas. In: Horseman, N.D. (eds) Prolactin. Endocrine Updates, vol 12. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1683-5_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5676-9
Online ISBN: 978-1-4615-1683-5
eBook Packages: Springer Book Archive